CTNM ▼ -10.3% - Contineum Therapeutics, Inc. $CTNM Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder Contineum Therapeutics stock fell 10.3% today following the company's announcement of Phase 2 results for JNJ-5120/PIPE-307 in major depressive disorder. The market's negative reaction suggests investors found the trial data disappointing or concerning relative to prior expectations for the program. 14-SEP-2026 04:06 PM ET